JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison.

ABSTRACT:

Background

Giant cell tumors of bone (GCTB) are RANK/RANK-ligand positive, progressive osteolytic tumors. There was no medical treatment for GCTB based on efficacy and safety data from Chinese patients. A single-arm, phase II study demonstrated the promising efficacy of JMT103 in unresectable or surgically challenging GCTB. Patient-level outcomes from the single-arm trial were compared with real-world data from denosumab or non-denosumab treated patients to estimate comparative efficacy in unresectable or surgically challenging GCTB.

Methods

The real-world data were retrospectively collected from three hospitals between January 2013 and December 2023. The eligibility criteria of the two cohorts were based on the JMT103 single-arm study. Propensity score matching was used to

SUBMITTER: Xu H 

PROVIDER: S-EPMC12647920 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature